Last reviewed · How we verify

Humira — Competitive Intelligence Brief

Humira (ADALIMUMAB) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: TNF blocker. Area: Oncology.

marketed TNF blocker Tumor Necrosis Factor-alpha (TNF-alpha) Oncology Monoclonal antibody Live · refreshed every 30 min

Target snapshot

Humira (ADALIMUMAB) — AbbVie. Adalimumab binds TNF-alpha and blocks interaction with p55 and p75 cell surface receptors.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Humira TARGET ADALIMUMAB AbbVie marketed TNF blocker Tumor Necrosis Factor-alpha (TNF-alpha) 2002-01-01
Abrilada Adalimumab-Afzb AbbVie marketed TNF blocker Tumor necrosis factor-alpha (TNF-alpha) 2002-01-01
Remicade Infliximab-Dyyb Johnson & Johnson marketed TNF blocker Tumor Necrosis Factor alpha (TNFα) 1998-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (TNF blocker class)

  1. AbbVie · 2 drugs in this class
  2. Johnson & Johnson · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Humira — Competitive Intelligence Brief. https://druglandscape.com/ci/adalimumab. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: